Latest Breaking News On - கூட்டுறவு இயக்குனர் - Page 1 : comparemela.com

nanoMesh™ LLC (a subsidiary of Exogenesis Corporation) Announces Secondary Endpoint Achieved in nanoMesh™ Pathogen Inhibiting Protein (PIP) Uptake Studies nanoMesh™, An Innovative Soft Tissue Repair Implant Possesses A Unique Nanometer-level Surface Texture News provided by Share this article Share this article BILLERICA, Mass., June 9, 2021 /PRNewswire/ nanoMesh™ LLC, a subsidiary of Exogenesis Corporation, announced today that it has successfully achieved the secondary endpoints for the nanoMesh™ Pathogen Inhibiting Protein (PIP) uptake studies. The PIP trials demonstrated controlled uptake [1] of a series of pathogen inhibiting, tissue integrating enhancing, and scar formation inhibition proteins [2], including fibronectin [6] and laminin [7] by nanoMesh™. nanoMesh™ possesses a unique nanometer-level surface texture, via the application of Accelerated Neutral Atom Beam (ANAB) technology

United statesKarl andrew leblancKarla leblancAmerican society of metabolicDrug administrationSociety for laparoendoscopic surgeonsSociety of american gastrointestinalAmericas hernia societyMaster of business administrationExogenesis corporationAmerican college of surgeonsExogenesis corporation completed firstSchool in shreveportPathogen inhibiting proteinAccelerated neutral atom beamBusiness administration